13F Holdings
中文EN

ANRO Alto Neuroscience, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1999480 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-52.9%
TTM EPS YoY-0.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-46.6%
ROA-40.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets9.2%
Debt / equity0.05x
Current ratio18.12x
Interest coverage-48.48x

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue———
R&D expense$45.62M$47.00M$30.29M
SG&A expense$20.75M$21.61M$7.52M
Operating income-$66.36M-$68.61M-$37.81M
Interest expense$2.47M$1.38M$1.37M
Income tax$0$0$0
Net income-$63.24M-$61.43M-$36.30M
EBITDA-$65.70M-$68.11M-$37.44M
EPS (basic)-2.19-2.50-9.73
EPS (diluted)-2.19-2.50-9.73
Weighted avg. shares (diluted)28.85M24.60M3.73M
Balance sheet
Cash & equivalents$176.48M$168.73M$82.55M
Current assets$177.72M$169.34M$85.39M
PP&E, net$1.87M$2.67M$1.11M
Total assets$184.69M$177.54M$86.63M
Current liabilities$11.32M$10.01M$5.61M
Short-term debt$585,000$0$0
Long-term debt$16.17M$10.25M$9.86M
Total debt$16.76M$10.25M$9.86M
Total liabilities$33.55M$26.08M$16.82M
Shareholders' equity$151.14M$151.46M-$71.67M
Net debt-$159.73M-$158.47M-$72.69M
Shares outstanding31.92M26.99M3.83M
Cash flow statement
Operating cash flow-$51.77M-$47.42M-$33.45M
Capital expenditure$24,000$2.08M$470,000
Free cash flow-$51.79M-$49.50M-$33.92M
Investing cash flow-$24,000-$2.08M-$470,000
Financing cash flow$60.08M$135.69M$68.13M
Depreciation & amortization$661,000$502,000$373,000
Stock-based compensation$8.11M$7.63M$2.89M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.